PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPSWEDNESDAY 23RD MAY 2018, HOLIDAY INN KENSINGTON FORUM, LONDON, UK

FEATURED HIGHLIGHTS IN 2018: •Explorethe possibilities of DNA-based, disease modifying

treatments for painful diabetic neuropathy withViroMed•Discoverthe latest approaches in translational science

with presentations on bridging the translational gap from EliLillyand MundipharmaResearchGmbH&Co.KG

•Overcomethe challenges of patient recruitment and the placebo response withNovartis

•LearnhowAstraZeneca andEliLilly are targeting ion channels to reduce pain

•Getinvolvedin round table discussions on chronic pain and depression, the opioid crisis, alternatives to animal models

CHAIRS FOR 2018:• JosephStauffer,Chief Medical Officer, CaraTherapeutics• RandallStevens,Chief Medical Officer,Centrexion• KerrieBrady, Chief Business Officer, Executive VP Corporate

Strategy, Centrexion

FEATURED SPEAKERS 2018:• IainChessell,VP & Head, IMED Neuroscience,AstraZeneca• TheoMeert, Head of Global Government Grant Office, JanssenPharmaceuticalNV,J&J

• AlexandrOksche,Executive Director Pharmacology and Translational Science,MundiPharma

• DanielMikol,Executive Medical Director, Global Neuroscience Development,Amgen

• YaninaFlossbach,Associate Medical Director Neuroscience, Novartis

• MarkField, Senior Vice President, Head of Global Clinical Development, GrunenthalGmbH

Holiday Inn Kensington Forum, London, UK

www.pain-therapeutics.co.uk Registeronlineorfaxyourregistrationto+44(0)8709090712orcall+44(0)8709090711

ACADEMIC&GROUPDISCOUNTSAVAILABLE @SMIPHARM #smipaintherapeutics

SMi presents the 18th annual conference on... CONFERENCE:

21ST - 22ND

WORKSHOPS: 23RD

MAY 2018

Pain Therapeutics Exploreinnovativeapproachesandnoveltargetsinanalgesicmedicine

B:Clinical,RegulatoryandMarketAccessAspects intheDevelopmentofMedicinalProductsintended

fortheTreatmentofPaininEuropeandUSAWorkshop Leader: SimonRuini,

Managing Director,PharmaDesignLimited

13.30-17.30

A:HowShouldTheLikelyFuture PainTherapeuticLandscapeInform

CurrentDrugDevelopment?Workshop Leader: JoanneTaylor,

Head of Neuroscience, PrescientHealthcareGroup 08.30-12.30

Sponsoredby

BOOKBY31STJANUARYTOSAVE£400BOOKBY28THFEBRUARYTOSAVE£200BOOKBY29THMARCHTOSAVE£100

PainTherapeutics DayOne|Monday21stMay2018www.pain-therapeutics.co.uk

08.30 Registration&Coffee

09.00 Chair’sOpeningRemarks JosephStauffer,Chief Medical Officer, CaraTherapeutics

TRANSLATIONAL APPROACHES

OPENING KEYNOTE09.10 Choosingtargetsfornovelanalgesics:mechanisticversus

opportunisticapproaches • Translatability of preclinical evidence is debated in the pain

field, but are there exceptions that prove (or disprove) the rule? • Alternatively, can we take an opportunistic approach

and focus on targets with clinical evidence provided by serendipity?

• This presentation will address these questions considering various examples including KCNQ2/3, TRP family, NGF and CGRP

JennyLaird,Senior Director, Search and Evaluation, EliLilly LisaBroad,Senior Research Advisor,Elililly

09.50 Drugdiscoveryapproachesinneuropathicpainandmigraine–applesandorangesorlemonsandlimes?

• Therapeutics target distinct facets of disease pathophysiology in neuropathic pain and migraine

• Shared neurobiological mechanisms in neuropathic pain and migraine

• Limitations to drug development – animal models and/or patient populations

• Harmonizing knowledge gained from neuropathic pain research and development with migraine drug discovery

GordonMunro,Senior Scientist,DanishHeadacheCentre

10.30 MorningCoffee

11.00 Translationalopportunitiesandchallengesinchronicpain • Where are we in our understanding of chronic pain and

appropriate cellular targets? • How to bridge the translational gap from preclinical models

to patient selection • Will personalised medicine provide us with new avenues for

mechanism-based treatments? • Risk signatures and biomarkers – what are the opportunities

and challenges in chronic pain? AlexanderOksche,Executive Director, MundipharmaResearch

GmbH&Co.KG

11.40 PanelDiscussion:PainvsNociception:Howappropriateistheuseofanimalmodelsinpaintherapeutics

• Role of animal models in the failure of pain therapeutic development

• How reliable are the surrogate markers for pain in animal models

• What are the alternatives to animal models • Why do pre-clinical trials still use animal models GordonMunro,Senior Scientist,DanishHeadacheCentre JennyLaird, Senior Director, Search and Evaluation,EliLilly AlexanderOksche, Executive Director,

MundipharmaResearchGmbH&Co.KG

12.20 NetworkingLunch

13.20 AbdominoplastyasaNovelAnalgesicModelforAcuteSoftTissuePain

• Abdominoplasty has been validated as an acute pain model with high assay sensitivity

• Subjects undergoing abdominoplasty have a relatively high incidence of opioid-based side effects. From an experimental standpoint, this is a positive because it provides an opportunity to demonstrate putative opioid-sparing properties of novel molecules

• There are several key design characteristics that are critical to the success of the model (intraoperative analgesia, specifics of the surgical procedure, provision of rescue drugs)

• The model has certain weaknesses that must be understood when designing clinical programs

NeilSingla,Founder and Chief Scientific Officer,LotusClinicalResearch

NOVEL TARGETS

CASE STUDY: 14.00 CR845:Anovelkappaopioidreceptoragonist

foracutepost-operativepain,chronicpain ofosteoarthritisandpruritus

• Discussion of unique pharmacology of CR845 • Analysis of respiratory safety and abuse liability

when used for treatment of pain • Summary of up to date results from phase II osteoarthritis trials • Future hopes for CR845 JosephStauffer,Chief Medical Officer,CaraTherapeutics

CASE STUDY14.40 CNTX-6970anovelCCR2antagonistwith

auniqueanalgesicsignature • Mechanism of action • Unique analgesic signature in preclinical models • Using Big Data to identify clinical development targets • Findings from Phase 1 clinical studies and next steps RandallStevens,Chief Medical Officer,

CentrexionTherapeuticsCorp

15.20 AfternoonTea

CASE STUDY15.50 VM202,aDNA-basedPotentialDisease-Modifying

TreatmentforPainfulDiabeticNeuropathy • VM202 is a naked plasmid DNA vector engineered

to express two isoforms of human hepatocyte growth factor (HGF)

• In an ongoing Phase 3 clinical study, VM202 (8 mg/leg) or Placebo is administered i.m. to the calf muscle of each leg in a defined multi-injection pattern on Days 0 and 14 and again on Days 90 and 104

• Phase I/II and separate Phase 2 results show robust reductions in foot pain (p<0.05 vs. baseline) and a trend in improved sensory function through 9-12 months after initial treatment in subjects receiving VM202

• Pain relieving effects were more pronounced in patients who are not taking Lyrica (pregabalin) and/or Neurontin (gabapentin)

• VM202 demonstrated an excellent safety profile in Phase I/II and Phase 2 clinical studies

WilliamSchmidt,Vice President, Clinical Development, ViroMed

DRUG DELIVERY AND TRIAL CONDUCT

CASE STUDY16.30 Zilretta:Developmentofanextendedrelease

intra-articulartherapeuticforosteoarthritis • Zilretta microsphere technology – how does it work? • The challenges of developing an extended release

product - Summary of pre-clinical data - Summary of clinical studies • Case study examples ToniWilliamson, Senior Director Non-Clinical Research,

FlexionTherapeutics

17.10 Trialconductinchronicpainconditions;Pitfallsandchallenges • Patient reported outcomes in clinical trials in pain • Reducing placebo responses • Patient recruitment challenges • Data handling and management • Other considerations YaninaFlossbach,Associate Medical Director,Novartis

17.50 Chair’sclosingremarksandcloseofdayone

Registeronlineat www.pain-therapeutics.co.uk

PainTherapeutics DayTwo|Tuesday22ndMay2018www.pain-therapeutics.co.uk

08.30 Registration&Coffee

09.00 Co-Chairs’OpeningRemarks RandallStevens,Chief Medical Officer, Centrexion KerrieBrady,Chief Business Officer, Executive VP Corporate

Strategy, Centrexion

TARGETING ION CHANNELS

09.10 TheTREK1agonists,apromisingwaytosolvetheopioidcrisis? • An example of TREK 1 agonists: the substituted acrilyc acid

derivatives • In vitro and in vivo pharmacological profile • Challenges and promises for the future JeanDeregnaucourt,Scientific Director, INNOPAIN

CASE STUDY 09.50 DevelopmentofNMDAreceptormodulators

incentralpaindisorders • The NMDA receptor is an attractive therapeutic

target for neuropathic and chronic pain disorders • The preclinical development, data and pharmacology

of NYX-2925 will be presented • The clinical development strategy for NYX-2925 will be

discussed TorstenMadsen, Chief Medical Officer, Aptinyx

10.30 MorningCoffee

11.00 SelectiveTARP-dependentAMPAReceptorAntagonists asaNovelTherapyforChronicPain

• The role of AMPA receptors in synaptic plasticity in pain pathways

• Expression and functional consequences of Transmembrane AMPA receptor Regulatory Proteins (TARPs)

• Identification of TARP-dependent AMPA receptor antagonists

• Evidence for LY3130481 (CERC-611) as a novel analgesic EricNisenbaum,Group Leader, Neurophysiology, EliLilly

CASE STUDY 11.40 Druggingtheun-druggable:P2X4mAbsas

therapeuticsforpain • Novel approaches to discovery of antibodies to P2X4 • Functional and electrophysiological characterisation • Reaching the CNS – application of novel BBB technologies

to access the spinal cord with antibody therapies • Efficacy in preclinical models and next steps IainChessell,VP & Head, IMED Neuroscience, AstraZeneca

ROUNDTABLEDISCUSSIONSESSIONS12.20 Depressionandchronicpain • Does constant pain cause depression or is depression a

co-symptom of pain caused by intrinsic changes to neurons? IainChessell,AstraZeneca • Opioid drugs – Amid an opioid crisis, do abuse resistant

drugs work and are we doing enough to reduce harm from opioids?

JosephStauffer,CaraTherapeutics • What can the pain therapeutics industry expect with the

ageing population? RandallStevens,Centrexion • How should patient engagement be managed clinical

trials for analgesic drugs to reduce the placebo effect and increase the success of clinical trials?

KerrieBrady,Centrexion • Why are novel analgesic targets so challenging to find

and target effectively with drugs?

JennyLaird,EliLilly • Can stem cells ever replace animal models in preclinical

studies? – Benefits and challenges. TheoMeert,J&J • Emerging therapeutics to treat migraine pain – what’s next

after CGRP? DanielMikol,Amgen

13.00 NetworkingLunch

CURRENT INDUSTRY OUTLOOK

14.00 BigDataforBigDecisions • How to best develop a portfolio of novel non-opioid

products for pain • Integration of human expertise and artificial intelligence • Using metadata to qualify big data output • Can Big Data increase technical success for novel pain

drug development? KerrieBrady,Chief Business Officer, Executive VP Corporate

Strategy, Centrexion

CASE STUDY14.40 DevelopmentupdateonErenumab • The calcitonin gene-related peptide (CGRP)

pathway is pathophysiologically relevant in migraine • Erenumab is an investigational monoclonal antibody

targeting the canonical receptor for CGRP • In episodic migraine prevention studies, erenumab has

demonstrated efficacy in reducing migraine frequency and use of acute headache medications

• In chronic migraine, erenumab has demonstrated efficacy in reducing migraine frequency and use of acute medications in patients with or without acute medication overuse

DanielMikol,Executive Medical Director, Global Neuroscience Development, Amgen

15.20 AfternoonTea

15.50 Newapproachestodevelopingpainproducts • Search for proof of concept testing • Search for alternative development plans • New marketing/entry strategies needed TheoMeert, Head of Global Government Grant Office,

JanssenPharmaceuticalNV,J&J

CASE STUDY16.30 NKTR-181-anovelapproachtoanold-school

target • Abuse liability of drugs is strongly related to

their CNS pharmacokinetics • NKTR-181 is a first-in-class opioid analgesic with strategic

brain entry kinetics • Limiting the rate of entry of mu-opioid agonists reduces

their likeability • NKTR-181’s inherent long circulating half-life reduces

withdrawal symptoms • Pivotal efficacy, safety, and abuse liability studies are

completed StephenDoberstein,Senior Vice President, Research and

Development and Chief R&D Officer,NektarTherapeutics

CLOSING KEYNOTE17.10 AnindustryperspectivefromGrunenthal • Approaching pain as a disease – not just a symptom • Mapping the landscape of pain • Using a target-to-disease approach to identify novel

compounds for development MarkField,Senior Vice President, Head of Global Clinical

Development, GrunenthalGmbH

17.50 CO-Chairs’ClosingRemarksandCloseofDayTwo

Registeronlineat www.pain-therapeutics.co.uk Alternativelyfaxyourregistrationto+44(0)8709090712orcall+44(0)8709090711

MARKETING OPPORTUNITIESWanttoknowhowyoucangetinvolved?Interestedinpromotingyourservicestothismarket?

ContactKyraWilliams,SMiMarketingon+44(0)2078276012oremail:kwilliams@smi-online.co.uk

Lotus Clinical Research is a specialty analgesic CRO, research site, and regulatory consulting firm supporting all phases of discovery for analgesic treatments, focused on improving the scientific accuracy of analgesic programs. Led by Dr. Neil Singla, Lotus focuses on optimizing design/conduct of clinical trials in pain, providing scientific leadership at every step of the development process. www.lotuscr.com

SPONSORSHIPANDEXHIBITIONOPPORTUNITIESSMioffersponsorship,exhibition,advertisingandbrandingpackages,uniquelytailoredtocomplementyourcompany’smarketingstrategy.Primenetworking

opportunitiesexisttoentertain,enhanceandexpandyourclientbasewithinthecontextofanindependentdiscussionspecifictoyourindustry.Shouldyouwishtojointheincreasingnumberofcompaniesbenefitingfromsponsoringourconferencespleasecall:AliaMalickon+44(0)2078276168oremail:amalick@smi-online.co.uk

Official MediaPartner:

Official Publications:

Supportedby:

SCIENTIFICADVISORYBOARD

The conference program was developed with the assistance from:

StevenKamerling,Senior Research Director, Zoetis

JosephW.Stauffer,DO, MBA, Chief Medical Officer, CaraTherapeutics,Inc.

RandallStevens, Chief Medical Officer, Centrexion

IainChessell, VP & Head, IMED Neuroscience, AstraZeneca

KerrieBrady,Chief Business Officer, Executive VP Corporate Strategy, Centrexion

ProudlySupportedBy

LETTER FROM THE CHAIRS:Dear Participants,

There has been a dearth of novel analgesics over the last couple of decades, resulting in a growing population of people whose acute and chronic pain needs are not being met by the relatively few analgesic classes of drugs we now have. The next wave of novel analgesics is making its way through Research and Development, potentially heralding a renaissance in analgesia, similar to that seen in rheumatology with the new antibodies and small molecules starting in the late 1990s, and the boom we are seeing in the immune-oncology area. In terms of the size of the population in need for better analgesics, it dwarfs cardiovascular, diabetes and oncology, combined. The acuteness of the lack of effective analgesics has raised increasing interest in key stakeholders in health authorities, industry, academia and payers.

The 18th SMi conference on Pain Therapeutics continues the education and discussion about the landscape of the current market, drugs in Research and Development, the regulatory challenges and opportunities, as well as the current value propositions. Looking forward, we will discuss what the pain landscape is likely to look like in 3-5 years, and how do potential regulatory changes and disruptive technologies impact this future. Furthermore, how can one differentiate one’s drug from others successfully in Research, Development and commercially in terms of patient, physicians and payers. The invited speakers and panelists, including CEOs, CMOs, CSOs and Development/Scientists will address these issues in their presentations, on panel discussions, and during time set aside for networking.

We look forward to meeting with you in London in May 2018!

JosephStauffer,Chief Medical Officer, CaraTherapeutics

RandallStevens,Chief Medical Officer, Centrexion

KerrieBrady,Chief Business Officer, Executive VP Corporate Strategy,Centrexion

SPONSOREDBY

Registeronlineat www.pain-therapeutics.co.uk

HowShouldTheLikelyFuturePainTherapeutic LandscapeInformCurrentDrugDevelopment?

HALF-DAY POST-CONFERENCE WORKSHOP AWEDNESDAY 23RD MAY 2018, HOLIDAY INN KENSINGTON FORUM, LONDON, UK 08.30-12.30

Registeronlineat www.pain-therapeutics.co.uk

Workshop Leader: JoanneTaylor,

Head of Neuroscience, PrescientHealthcareGroup

HALF-DAYPOST-CONFERENCEWORKSHOPBWEDNESDAY 23RD MAY 2018, HOLIDAY INN KENSINGTON FORUM, LONDON, UK 13.30-17.30

WorkshopOverviewIn response to continuing unmet need, there is a high number of novel drugs in the pain therapeutics pipeline. For those developing new drugs, it is important to consider what the future landscape is likely to look like at the time of launch and how this should inform current activities. Active participation in the workshop will be highly encouraged.

Whyshouldyouattend?Delegates will be encouraged to consider how their drugs fit into a future pain therapeutics landscape and what action they should be considering now to maximise their chances of success.

AbouttheworkshopleaderJoanneTaylor,who has a PhD in developmental neuroscience from King’s College London, heads up Prescient’s neuroscience business. After completing a postdoctoral fellowship, she joined Eisai. Over her 18-year career there, she led global teams in the discovery of novel therapeutic strategies for neurological conditions. As Director of Strategic Research Planning, she led reviews of Eisai’s neuroscience portfolio to identify areas of major focus and investment. Since joining Prescient in 2011, Joanne has supported portfolio, clinical, regulatory and commercial strategies for a wide array of clients. She is a seasoned workshop moderator.

Prescient Healthcare Group is a specialty biopharmaceutical product strategy and decision support consultancy that helps our clients make better clinical and commercial decisions, resulting in

improved outcomes for patients, customers and shareholders. From our offices in London, New York, San Francisco, New Delhi and Beijing, our three specialist practices provide decision support to various pharmaceutical functions (InflexionRx), develop strategies that make our clients’ assets stand out from the competition(VantageRx),and align cross-functional teams on product strategy(FusionRx).

Agenda

08.30 RegistrationandCoffee

09.00 Openingremarksandintroductions

09.10 Overviewofthecurrentpaintherapeuticslandscape • Current market • Drugs in development • Regulatory challenges • Current value propositions

09.50 Howisthepaintherapeuticslandscapelikely tochangeinthenext3-5years?

• Novel mechanisms • Disruptive technologies • Regulatory changes • Future access requirements

10.30 MorningCoffee

11.00 Howcandrugsindevelopmentsuccessfullydifferentiateinthefuturepaintherapeuticsmarket?

• Critical success factors in the future market • Future stakeholders • Differentiated future value propositions

11.40 Practicalstepstowardfuturesuccess • Open discussion on practical steps to plan for

success in the future pain therapeutics market

12.20 Closingremarks

12.30 Endofworkshop

WorkshopOverview:The first section of this workshop will provide key aspects of EU and US marketing applications that have succeeded and those that have failed looking at relevant endpoints, patient populations and outcome measures.

The second part of the workshop will focus on Market Access opportunities and unmet need for new medicinal products intended for the treatment of pain in Europe and USA.

Whyshouldyouattend• This interactive workshop will introduce participants to a 360° approach to Regulatory

challenges and opportunities related to the development of Pain Treatment Products

• The workshop will illustrate Clinical Development aspects aimed at the successful design and execution of clinical studies through an analysis of unmet needs, endpoints and outcomes

• You will finally be able to gather insights on current treatment practice and Market drivers for future Neuropathic, Chronic and Post-Operative Pain treatment products

Aboutthehost:SimonRuiniis Managing Director of Pharma Design Limited, a boutique service provider for the biotech and pharmaceutical industry. Simon is a well-qualified professional with broad experience in Regulatory, Safety and Clinical Development in the pharma and biotech. He specializes in Marketing Authorisation filings in EU and Clinical Study design. Simon is a visiting lecturer at UNIGE in Geneva and ETH in Zurich. During his consulting career Simon has provided advice and work for Roche-Genentech, Eli Lilly, Sanofi, Novartis, Norgine, Mitsubishi Tanabe, Alliance Unichem.

Pharma Design is a small service provider with a network of specialised consultants assisting Pharmaceutical Companies & Biotechs in achieving Marketing Authorisations in Europe and

preparing adequately for Market launch. The Company provides assistance with Clinical Study design, Marketing Applications and Drug Safety services (i.e. Pharmacovigilance) during drug development and post-marketing.

Workshop Leader: SimonRuini,

Managing Director, PharmaDesignLimited

Agenda

13.30 RegistrationandCoffee

14.00 Openingremarksandintroductions

14.10 GuidelinesandRegulatoryAspectsregardingClinicalDevelopmentofproductsintended forthetreatmentofpain

• Comparison of guidelines and regulatory aspects in EU and USA

• Definitions and indications • EMA and FDA Guidance • Claims and labelling • Limitations of established pain classifications

14.50 ClinicalStudydesignforthedevelopmentofproductsintendedforthetreatmentofpain

• Clinical endpoints • Choice of comparators • Patient Populations • Outcome measures • Unmet needs

15.30 AfternoonTea

16.00 RecentLicenseApprovalsinEUandUSA • Recent EMA and FDA License approvals • What has convinced regulators? • What has not convinced regulators?

16.40 Inflammatory,ChronicandPost-operativepaintreatments-MarketopportunitiesinE.U.andU.S.A.

• Patient Journeys • Market objectives • Prescribing trends in EU and USA

17.20 ClosingRemarks

17.30 EndofWorkshop

Clinical,RegulatoryandMarketAccessAspectsintheDevelopment ofMedicinalProductsintendedfortheTreatmentofPaininEuropeandUSA

PAIN THERAPEUTICS Conference:Monday 21st & Tuesday 22nd May 2018, Holiday Inn Kensington Forum, London, UK

Workshops: Wednesday 23rd May 2018, Holiday Inn Kensington Forum, London, UK

4WAYSTOREGISTERONLINEatwww.pain-therapeutics.co.uk

FAX your booking form to +44 (0) 870 9090 712

PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd,

Ground & First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

JobTitle:

Department/Division:

Company/Organisation:

Email:

CompanyVATNumber:

Address:

Town/City:

Post/ZipCode: Country:

DirectTel: DirectFax:

Mobile:

Switchboard:

Signature: Date:I agree to be bound by SMi’s Terms and Conditions of Booking. ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address(ifdifferentfromabove):

Town/City:

Post/ZipCode: Country:

DirectTel: DirectFax:

Payment:If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.Substitutions/NameChanges:If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate.Cancellation:If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.Alterations:It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.DataProtection:The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updatesquotingtheURNasdetailedaboveyouraddressontheattachedletter.

IfyouhaveanyfurtherqueriespleasecalltheEventsTeamontel+44(0)8709090711oryoucanemailevents@smi-online.co.uk

□ PleasecontactmetobookmyhotelAlternativelycalluson+44(0)8709090711,email:events@smi-online.co.ukorfax+44(0)8709090712

UniqueReferenceNumber

OurReference LVP-249

EARLYBIRDDISCOUNT

□ Bookby31stJanuarytoreceive£400offtheconferenceprice□ Bookby28thFebruarytoreceive£200offtheconferenceprice□ Bookby29thMarchtoreceive£100offtheconferenceprice

DELEGATE DETAILS

TermsandConditionsofBooking

Payment must be made toSMiGroupLtd,and received before the event, by one of the following methodsquotingreferenceP-249andthedelegate’sname.Bookingsmadewithin7daysoftheeventrequirepaymentonbooking,methodsofpayment:

□ UKBACS Sort Code 300009,Account 00936418□ WireTransfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013,Account 00936418 IBAN GB48LOYD30000900936418□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ CreditCard □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.

Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder’sName:

Signature: Date:I agree to be bound by SMi’s Terms and Conditions of Booking.

CardBillingAddress (If different from above):

PAYMENT

VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________

VAT

IcannotattendbutwouldliketopurchaseaccesstothefollowingDocumentPortal/papercopydocumentation Price Total□ Access to the conference documentation

on the Document Portal £499.00 +VAT £598.80□ The Conference Presentations – paper copy £499.00 - £499.00

(or only £300 if ordered with the Document Portal)

DOCUMENTATION

VENUE HolidayInnKensingtonForum,97CromwellRd,LondonSW74DN,UK

CONFERENCE PRICES

Iwouldliketoattend:(Please tick as appropriate) Fee Total

□ Conference & 2 Workshops £2697.00 +VAT £3236.40□ Conference & 1 Workshop A □ B □ £2098.00 +VAT £2517.60□ Conference only £1499.00 +VAT £1798.80□ 2 Workshops £1198.00 +VAT £1437.60□ 1 Workshop only A □ B □ £599.00 +VAT £718.80

PROMOTIONALLITERATUREDISTRIBUTION

□ Distribution of your company’s promotional literature to all conference attendees £999.00 +VAT £1198.80

The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference.